This is a working overview of GHRH analog, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-02-15. Anything still debated is marked as such rather than presented as settled.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | Matches human GHRH(1-44) length |
| N-terminal modification | trans-3-hexenoyl group | Confers resistance to dipeptidyl peptidase IV |
| Appearance | White to off-white powder | Typically supplied lyophilized in a sealed vial |
| Solubility class | Freely soluble in water | Hydrophilic peptide; polar solvent compatible |
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
== Legal status == In the United States, chloral hydrate is a schedule IV controlled substance and requires a physician's prescription. Its properties have sometimes led to its use as a date rape drug. The phrase, "slipping a mickey," originally referred specifically to adding chloral hydrate to a person's (alcoholic) drink without the person's knowledge.
=== Naming === In Mendeleev's nomenclature for unnamed and undiscovered elements, meitnerium would be called eka-iridium. In 1979, during the Transfermium Wars (but before the synthesis of meitnerium), IUPAC published recommendations per which the element was to be called unnilennium (symbol Une), a systematic element name as a placeholder, until the element is discovered (and the discovery then confirmed) and a permanent name is decided on. Though widely used in the chemical community on all levels, from chemistry classrooms to advanced textbooks, the recommendations were mostly ignored among scientists in the field, who either called it "element 109", with the symbol E109, (109) or even simply 109, or used the proposed name "meitnerium". The naming of meitnerium was discussed in the Transfermium Wars regarding the names of elements 104–109, but meitnerium was the only proposal and thus was never disputed. The name meitnerium (Mt) was suggested by the GSI team in September 1992 in honor of Austrian physicist Lise Meitner, a co-discoverer of protactinium (with Otto Hahn), and one of the discoverers of nuclear fission. In 1994 the name was recommended by IUPAC, and was officially adopted in 1997. It is thus the only element named solely after a non-mythical woman (curium is named for both Pierre and Marie Curie).
== Transportation == Retford railway station, Nottinghamshire, England (station code: RET) Rotterdamse Elektrische Tram, the main public transport operator of Rotterdam, the Netherlands Røst Airport, Norway (IATA code) Rapid-exit taxiway allowing an aircraft to leave a runway quickly
Sources: en.wikipedia.org
The sinuses, like other air-filled cavities, are susceptible to barotrauma if their openings become obstructed. This can result in pain as well as epistaxis (nosebleed). Diagnosis is usually simple provided the history of pressure exposure is mentioned. Barosinusitis, is also called aerosinusitis, sinus squeeze or sinus barotrauma. Sinus barotrauma can be caused by external or internal overpressure. External over-pressure is called sinus squeeze by divers, while internal over-pressure is usually referred to as reverse block or reverse squeeze.
==== Sulfur ==== The sulfur stable isotope system is based on small, mass-dependent fractionations of sulfur isotopes. These fractionations are reported relative to Canyon Diablo Troilite (V-CDT), the agreed upon standard. The ratio of the most abundant sulfur isotope, 32S, compared to rarer isotopes such as, 33S, 34S, and 36S, is used to characterize biological signatures and geological reservoirs. The fractionation of 34S (δ34S) is particularly useful since it is the most abundant of the rare isotopes. This system is less commonly used on its own and typically complements studies of carbon and nitrogen. In bioarchaeology, the sulfur system has been used to investigate paleodiets and spatial behaviors through the analysis of hair and bone collagen. Dietary proteins incorporated into living organisms tend to determine the stable isotope values of their organic tissues. Methionine and cysteine are the canonical sulfur-containing amino acids. Of the two, δ34S values of methionine are considered to better reflect isotopic compositions of dietary sulfur, since cysteine values are impacted by diet and internal cycling. While other stable isotope systems have significant trophic shifts, sulfur shows only a small shift (~0.5‰).
== Notable publications == Merck & Co. publishes The Merck Manuals, a series of medical reference books for physicians, nurses, technicians, and veterinarians. These include the Merck Manual of Diagnosis and Therapy, the world's best-selling medical reference. The Merck Index, a compendium of chemical compounds, was published by Merck & Co. until it was acquired by the Royal Society of Chemistry in 2012.
Sources: en.wikipedia.org
Nana Mary's last appearance is midway through season nine, in which she finally has a heart-to-heart with Bev, thus closing the story on their relationship. Despite her absence, Mary appears at other family occasions, including the birth of her great-great-granddaughter. In the reboot and spin-off, D.J. and Geena's daughter is named after Nana Mary, who has since died.
Mifamurtide is muramyl tripeptide phosphatidylethanolamine (MTP-PE), a synthetic analogue of muramyl dipeptide. The side chains of the molecule give it a longer elimination half-life than the natural substance. The substance is applied encapsulated into liposomes (L-MTP-PE). Being a phospholipid, it accumulates in the lipid bilayer of the liposomes in the infusion.
Naturally occurring tungsten (74W) consists of five isotopes. Four are considered stable (182W, 183W, 184W, and 186W) and one is slightly radioactive, 180W, with an extremely long half-life of (1.59±0.05)×1018 years. This results in about two alpha decays of 180W per gram of natural tungsten per year, so for most practical purposes, 180W can be considered stable. The other naturally occurring isotopes are also capable of alpha decay and so only observationally stable. Artificial radioisotopes of tungsten have been observed from 156W to 197W, the most stable of which are 181W with a half-life of 120.96 days, 185W with a half-life of 75.1 days, 188W with a half-life of 69.77 days and 178W with a half-life of 21.6 days. All of the remaining radioactive isotopes have half-lives less than one day, and most of these less than 8 minutes. The most stable known meta state is 179m1W with half-life 6.40 minutes.
The five other countries, including the second and third largest beef producers, France and the United Kingdom, respectively, permitted their use. This had resulted in disputes, with countries that had no prohibitions arguing that the restrictions by the others acted as non-tariff trade barriers. In response to the public outcry, in combination with the discovery that DES was a teratogen, in 1980 the EU began to issue regulations, beginning with prohibiting the use of stilbenes and thyrostatics by the European Community Council of Agriculture Ministers in 1980, and commissioning of a scientific study into the use of estradiol, testosterone, progesterone, trenbolone, and zeranol in 1981. The European Consumers' Organisation (BEUC) lobbied for a total ban upon growth hormones, opposed, with partial success, by the pharmaceutical industry. (In 1987 the European Federation of Animal Health (FEDESA), formed to represent, amongst other things, companies that manufactured growth hormones.) Neither European farmers nor the meat processing industry took a stance on the matter. With the help of the BEUC consumer boycotts of veal products, sparked by the Italian scandals and similar reports in France and Germany, spread across the EU, causing companies such as Hipp and Alete to withdraw their veal products, while veal prices dropped in France, Belgium, West Germany, Ireland, and the Netherlands. Because of the fixed purchases guaranteed by the EU's Common Agricultural Policy, ECU 10 million came out of the EU budget.
Sources: en.wikipedia.org
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.
No. It is a receptor agonist that stimulates the pituitary to release endogenous growth hormone. It does not contain or deliver growth hormone. Its downstream effects therefore depend on a functioning pituitary and an intact signaling pathway.
Pituitary responsiveness, receptor availability, and the natural pulsatility of the growth hormone axis all contribute. Because the compound amplifies an existing release pattern rather than overriding it, timing and physiological state matter. Individual variability in response is well documented but not fully explained.
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.